Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.